Clinical Trials
Clinical trials test new treatments to find better ways to prevent, detect or treat disease. Both healthy people and people with a disease or condition can volunteer to be part of a trial.
Cancer Care Services participate in a range of clinical trials at our hospitals. For information about any of the trials below, ask your doctor or nurse.
For information about clinical trials in general visit the Australian Clinical Trials website or search the Australia and New Zealand Clinical Trials Registry.
| Disease | Trial name | Trial description | Hospital |
|---|---|---|---|
| Acute Leukaemia | ALLG AML M21 | A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia AML M21 | RBWH |
| Acute Leukaemia | ALLG NBCR | Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry | RBWH |
| Acute Lymphoblastic Leukaemia | ALLG LS17 REGALLIA | Registry of acute lymphoblastic leukaemia in Australasia associated correlative studies | RBWH |
| Acute Myeloid Leukaemia | MINERAL | Magnetic Resonance Imaging and Quantitative Susceptibility Mapping (MRI-QSM) of brain iron to identify Chemotherapy Associated Neurocognitive Impairment (CANI) in Acute Myeloid Leukaemia (AML) | RBWH |
| Brain | GBM - BIOMARKERS | Non-Invasive Biomarkers In Glioblastoma - A Pilot Study | RBWH |
| Breast | AVATAR | Stereotactic Ablative Radiotherapy for Oligoprogressive ER-positive Breast Cancer | RBWH |
| Breast | BRCA-P | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation | RBWH |
| Breast | CA209-7FL | A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerReceptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer | RBWH |
| CNS | EX-TEM | Phase III Trial of Extended Temozolomide in Newly Diagnosed Glioblastoma | RBWH |
| CNS | MAGMA | MAGMA Trial: The Multi-Arm GlioblastoMa Australasia Trial | RBWH |
| EGFR NSCLC | ILLUMINATE | A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) | TPCH |
| Genito-Urinary | BEP | A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours. | RBWH |
| Genito-Urinary | ePAD | ePAD (Electronic CRPC Australian Database): Analyzing Treatment Patterns and Outcomes from Real-World Patients with Castrate-Resistant Prostate Cancer (CRPC) | RBWH |
| Genito-Urinary | ENZA-p | A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) | RBWH |
| Genito-Urinary | AMPLITUDE | A phase 3 randomised, placebo-controlled, double-blind study of niraparib in combination with abiraterone acetate and prednisone (AA-P) and ADT versus abiraterone acetate and prednisone and ADT in subjects with metastatic castration sensitive prostate cancer (mCSPC) with DNA-repair gene defects. | RBWH |
| Genito-Urinary | KEYNOTE B61 | A Phase 2, Open Label, Study of Pembrolizumab + Lenvatinib for 1L nccRCC (advanced or metastatic nccRCC) | RBWH |
| Genito-Urinary | KEYNOTE U03 | MK-3475-U03: A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYNOTE-U03) | RBWH |
| Genito-Urinary | KEYNOTE U03A | A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03A | RBWH |
| Genito-Urinary | KEYNOTE U03B | A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (U03): Substudy 03B | RBWH |
| Genito-Urinary | UNICAB | A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802). | RBWH |
| Genito-Urinary | KEYNOTE 365 | Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365). | RBWH |
| Genito-Urinary | UpFrontPSMA | A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer | RBWH |
| Genito-Urinary | KEYPAD | KidnEY cancer Pembrolizumab And Denosumab: Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) | RBWH |
| Gynaecological | iPRIME | A Phase 2, open label study of durvalumab and tremilimumab in combination with neoadjuvant carboplatin and paclitaxel in newly diagnosed advanced high grade serous ovarian cancer. | RBWH |
| Gynaecological | KEYNOTE A18 | A randomised, Phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer. | RBWH |
| Gynaecological | EMBRACE | Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2 (CTC0160 The EMBRACE study) | RBWH |
| Gynaecological | VESPA | A phase 2 study of the use of vaginal oestriol to prevent vaginal stenosis in patients treated with pelvic radiotherapy for gynaecological, rectal and anal malignancies | RBWH |
| Gynaecological | ICON 9 | An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy | RBWH |
| Gynaecological | AtTEnd | Phase III Double-Blind Randomized Placebo Controlled Trial of Atezolizumab in Combination with Paclitaxel and Carboplatin in Women With Advanced/Recurrent Endometrial Cancer (Atezolizumab Trial in Endometrial cancer - AtTEnd) | RBWH |
| Haem - Other | PROs in CARTs | Patient reported outcomes (PROs) in patients undergoing chimeric antigen receptor T cell therapies (CAR Ts). | RBWH |
| Haem - Other | COVEM | COVID-19 Vaccine Efficacy in patients with Haematological Malignancy “COVEM”. | RBWH |
| Haem - Other | National Projects with CanTeen | The Youth Cancer Service Experience of Care Survey (YCS EoC). | RBWH |
| Haem - Other | MoST Framework | The Cancer Molecular Screening and Therapeutics (MoST) Program - A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need. | RBWH |
| Haem - Other | NCAs in CARTs | Neurocognitive assessment in patients undergoing chimeric antigen receptor therapy | RBWH |
| Haem - Other | Phase 1 MB.CART19.1 CarT | Phase I Clinical Trial of MB.CART19.1 CD19 Chimeric Antigen Receptor (CAR) T Cells in Relapsed or Refractory CD19-Positive Haematological Malignancy | RBWH |
| Haem - Other | QMGP | Queensland Myeloid Genomics Program (QMGP) Evaluation | RBWH |
| Haem - Other | Nkarta NKX019 | A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-cell Malignancie. | RBWH |
| Haemophilia | BMN 270-303 | A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector–Mediated Gene Transfer of Human Factor VIII, with Prophylactic Corticosteroids in Hemophilia A Patients | RBWH |
| Head and Neck | SPIT | A simple saliva test to diagnose head and neck cancer at an early stage - head and neck cancer detection is a spitting distance away | RBWH |
| Head and Neck | P2191 | Development of an Adoptive T Cell Therapy for HPV-Associated Malignancies | RBWH |
| Head and Neck | C-POST | Phase III trial of postoperative radiotherapy with or without REGN2810 in high risk cutaneous squamous cell carcinoma of the head and neck (cSCCHN) | RBWH |
| Head and Neck | INDUCE-3 (GSK 209229) | A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with PD-L1 positive recurrent or metastatic HNSCC (209229). | RBWH |
| Head and Neck | ASPEN-04 | A Phase 2 Study of ALX148 in Combination with Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma | RBWH |
| Head and Neck | KEYNOTE 689 | A Phase 3, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage 3-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | RBWH |
| Hodgkin Lymphoma | PLIMATH | A multi-centre Phase II study to determine the response kinetics, safety and efficacy of pembrolizumab as frontline treatment of patients with Hodgkin Lymphoma considered unsuitable for ABVD | RBWH |
| Leukaemia | ALLG CML13 ASCEND | A single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia | RBWH |
| Leukaemia - MPN | IMAGO IMG-7289 | A Phase 2 Multi-Center, Open Label Study to Assess the Safety, Efficacy and Pharmacodynamics of IMG-7289 in Patients with Essential Thrombocythemia | RBWH |
| Lower GI | BREAKWATER (C4221015) | An open-label, multicenter, randomized phase 3 study of first-line Encorafenib plus Cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of Encorafenib and Cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer. | RBWH |
| Lower GI | LYNK-003 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable orMetastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) | RBWH |
| Lower GI | CHALLENGE | A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer: a randomised controlled trial | RBWH |
| Lower GI | RBWH & TPCH Database | The RBWH and TPCH metastatic Colorectal Cancer database: a prospective observational cohort study examining clinical and molecular biomarkers | RBWH |
| Lower GI | TRACC | TRACC (Biogrid): Study of Clinical Outcomes and Analysis of Bevacizumab use in Metastatic Colorectal Cancer | RBWH |
| Lower GI | MK4280A-007 | A Phase 3 study of MK-4280A Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer | RBWH |
| Lower GI | MONARCC | A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer. | TPCH |
| Lower GI | DYNAMIC III (ctDNA-08) | Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study | RBWH |
| Lower GI | DESTINY-CRC02 | A phase II study for the treatment of HER2- positive locally advanced unresectable or metastatic colorectal cancer subjects (CRC). | RBWH |
| Lung | KEYNOTE 867 | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) | RBWH |
| Lymphoma - HD | PLIMATH | A multi-centre Phase II study to determine the response kinetics, safety and efficacy of pembrolizumab as frontline treatment of patients with Hodgkin Lymphoma considered unsuitable for ABVD | RBWH |
| Lymphoma - Other | MoST LLY 15 AZ | A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma. | RBWH |
| Lymphoma - Other | GENMAB GCT3013-01 | A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma | RBWH |
| Mesothelioma | DREAM3R | DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial | TPCH |
| Metastatic NSCLC | LOXO-RET-18037 | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) | TPCH |
| Multiple Solid Tumours | Keynote 158 (BASKET) | A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors | RBWH |
| Myeloma | MRDR | Myeloma and Related Diseases Registry | RBWH |
| Myeloma - MM | JANSSEN CARTITUDE 4 MMY3002 | A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, vs Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma | RBWH |
| NETs | NET Sanguis | The potential role of circulating DNA in the management of neuroendocrine tumours. | RBWH |
| Other | INFOCUS | Peripheral Neuropathy in Chemotherapy-treated Patients: Predictors, Assessment strategies and Functional Outcomes. INFOCUS Study | RBWH |
| Pancreas | FOLFIRINOX | Prospective evaluation of FOLFIRINOX for metastatic of locally advanced Pancreatic Cancer | RBWH |
| Pancreas | PURPLE | Pancreatic cancer: Understanding Routine Practice and Lifting End results (PURPLE) Registry. A Prospective Pancreatic Cancer clinical registry. | RBWH |
| Phase I / Solid Tumours | R3767-ONC-1613 | A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies | RBWH |
| Prostate | DASL-HICAP | A randomized phase 3 trial of adding darolutamide to radiation and androgen deprivation therapy in high risk, clinically localized prostate cancer - DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized High-Risk Cancer of the Prostate | RBWH |
| Rectal | SPAR | A randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer | RBWH |
| Skin | HUYA Melanoma | HBI-8000-303: A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined with Nivolumab versus Placebo with Nivolumab in Patients with Unresectable or Metastatic Melanoma Not Previously Treated with PD-1 or PD-L1 Inhibitors | RBWH |
| Skin | I-MAT | MASC 03.18 I-MAT Trial - A randomised, placebo-controlled, phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma | RBWH |
| Skin | CA209-76K | A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma. | RBWH |
| Skin | CRIO | Chemoradiation for unresectable Skin Tumour with Immunotherapy | RBWH |
| Skin | R2810-ONC-1540 | A Phase 2 study of REGN2810, a fully human monoclonal anitbody to programmed death – 1 (PD1), in patients with advanced cutaneous squamous cell carcinoma | RBWH |
| Skin | STOP-GAP (ME-13) | A randomised phase III study of duration of Anti-PD-1 therapy in metastatic melanoma | RBWH |
| Skin | GoTHAM | A Merkel Cell Carcinoma (MCC) study testing the immunotherapy drug Avelumab in combination with either radionuclide therapy or external beam radiotherapy. | RBWH |
| Transplant | ALLG BM12 CAST |
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis
|
RBWH |
| Transplant - aGVHD | MODULAATE – CSL964_2001 | Phase 2/3, Multicenter, randOmized, Double-blind, placebo-controlled, stUdy to evaLuate the safety and efficacy of Alpha-1 AntiTrypsin for the prEvention of graft-versushost disease in patients receiving hematopoietic cell transplant (MODULAATE Study) | RBWH |
| Transplant - Transplant | SYNEOS REVC006 | Randomized, double-blind, placebo-controlled trial of the safety, tolerability, and efficacy of RV521 in the treatment of adult subjects who have undergone hematopoietic cell transplantation (HCT) with a documented upper respiratory tract infection (URTI) with respiratory syncytial virus (RSV) | RBWH |
| Upper GI | LEAP-015 | Pembrolizumab plus Lenvatinib plus Chemotherapy for the treatment of advanced/metastatic HER2 negative gastric/gastroesophageal junction adenocarcinoma (MK-7902-015) | RBWH |
| Upper GI | Neo-CREATE | Neoadjuvant Immune-Chemo-Radiotherapy in operable oEsophageal and gastro-oesophageal junction cancers with Carboplatin Paclitaxel Radiotherapy and Avelumab - a Trial assessing feasibility and preliminary Efficacy | RBWH |
| Upper GI | INTEGRATE II | INTEGRATE II trial, a Phase III study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC). | RBWH |
| Upper GI | Dynamic Pancreas | Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study | RBWH |
| VG161-A101 | VG161-A101 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies | RBWH |